物质信息

ID:537

名称和标识
商标名
XalatanXalatan Fixed Flow Device
IUPAC标准名
propan-2-yl (5E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
别名
Latanoprostlatanoprost
IUPAC传统名
latanaprost
数据登录号
化合物性质
理化性质
溶解度
8 mg/mL
疏水性(logP)
4.4
描述信息
Drug Groups
approved; investigational
Description
Latanoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes.

It is also known by the brand name of Xalatan manufactured by Pfizer.
Indication
For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Pharmacology
Latanoprost is an isopropyl ester prodrug which is inactive but which becomes active after hydrolysis to the acid from. Latanoprost opthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes.
Toxicity
Symptoms of overdose include bloodshot eyes and eye irritation.
Affected Organisms
Humans and other mammals
Biotransformation
Primarily hepatic (none except hydrolysis in the eye). Latanoprost is an isopropyl ester prodrug. It is hydrolyzed by esterases in the cornea to latanoprost acid, which is biologically active. The portion of the latanoprost acid that reaches the systemic circulation is metabolized primarily by the liver to 1,2-dinor and 1,2,3,4-tetranor metabolites by fatty acid beta-oxidation.
Absorption
Latanoprost is well absorbed through the cornea where the isopropyl ester prodrug is hydrolyzed to the acid form. Peak concentration is reached 2 hrs after topical administration.
Half Life
17 minutes
Clearance
* 7 mL/min/kg
References
• Hara T: [Increased iris pigmentation after use of latanoprost in Japanese brown eyes] Nippon Ganka Gakkai Zasshi. 2001 May;105(5):314-21. [Pubmed]
分子图谱
暂无数据
点击上传数据
参考文献
• Hara T: [Increased iris pigmentation after use of latanoprost in Japanese brown eyes] Nippon Ganka Gakkai Zasshi. 2001 May;105(5):314-21. Pubmed